東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Mechanisms of Progression of Disease...

Herrera, Natalia.

FindBook

Google Book

Amazon

博客來

Mechanisms of Progression of Disease in Autoimmune Myocarditis.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Mechanisms of Progression of Disease in Autoimmune Myocarditis./
作者:	Herrera, Natalia.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
面頁冊數:	35 p.
附註:	Source: Masters Abstracts International, Volume: 82-01.
Contained By:	Masters Abstracts International82-01.
標題:	Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27994659
ISBN:	9798617083943

Mechanisms of Progression of Disease in Autoimmune Myocarditis.
Herrera, Natalia.

Mechanisms of Progression of Disease in Autoimmune Myocarditis. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 35 p.

Source: Masters Abstracts International, Volume: 82-01.

Thesis (M.S.)--The University of Texas at San Antonio, 2020.

This item must not be sold to any third party vendors.

Autoimmune myocarditis is an inflammatory disease of the myocardium with variable etiology and clinical manifestations. While myocarditis is self-limiting in most patients, it can progress to dilated cardiomyopathy (DCM). In DCM, the heart undergoes fibrotic remodeling that is associated with left ventricular dysfunction and heart failure, which may lead to a need for a heart transplant. Current treatments focus on supportive therapy rather than preventing the progression of disease; this is the case with glucocorticosteroids (GCs) such as Dexamethasone (Dex) which treat inflammation. It is known that Dex administration upregulates the cytokine macrophage migratory inhibition factor (MIF) which in turn can counteract the effect of GCs. Using the experimental autoimmune myocarditis (EAM) model in BALB/c mice, we demonstrated that Dex therapy in the absence of MIF ameliorated the severity of both acute phase EAM and chronic phase DCM. However, despite a decrease in inflammatory infiltrates and fibrotic remodeling, the autoimmune peripheral T cell response was comparable between groups, suggesting that progression towards DCM implicating some other mechanism driving progression. Additionally, qPCR for extracellular matrix and chemotactic genes among others showed a decrease in osteopontin (OPN) production in MIF-inhibited Dex treated mice. Subsequently, heart infiltrates were compared in Wt vs OPN knockout mice; though not statistically significant, they were decreased in OPN knockout mice. To determine a possible direct link between OPN and MIF, cardiac fibroblasts were treated with recombinant MIF and cytokine production evaluated by ELISA. Our findings reveal insights into the mechanisms driving progression of autoimmune myocarditis to DCM.

ISBN: 9798617083943Subjects--Topical Terms:

611031
Immunology.
Subjects--Index Terms:

Autoimmune myocarditis

Mechanisms of Progression of Disease in Autoimmune Myocarditis.
LDR:02831nmm a2200337 4500 001 2269443
005 20200908090514.5
008 220629s2020 ||||||||||||||||| ||eng d
020 $a 9798617083943
035 $a (MiAaPQ)AAI27994659
035 $a AAI27994659
040 $a MiAaPQ $c MiAaPQ
100 1 $a Herrera, Natalia. $3 3546781
245 1 0 $a Mechanisms of Progression of Disease in Autoimmune Myocarditis.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 35 p.
500 $a Source: Masters Abstracts International, Volume: 82-01.
500 $a Advisor: Forsthuber, Thomas.
502 $a Thesis (M.S.)--The University of Texas at San Antonio, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Autoimmune myocarditis is an inflammatory disease of the myocardium with variable etiology and clinical manifestations. While myocarditis is self-limiting in most patients, it can progress to dilated cardiomyopathy (DCM). In DCM, the heart undergoes fibrotic remodeling that is associated with left ventricular dysfunction and heart failure, which may lead to a need for a heart transplant. Current treatments focus on supportive therapy rather than preventing the progression of disease; this is the case with glucocorticosteroids (GCs) such as Dexamethasone (Dex) which treat inflammation. It is known that Dex administration upregulates the cytokine macrophage migratory inhibition factor (MIF) which in turn can counteract the effect of GCs. Using the experimental autoimmune myocarditis (EAM) model in BALB/c mice, we demonstrated that Dex therapy in the absence of MIF ameliorated the severity of both acute phase EAM and chronic phase DCM. However, despite a decrease in inflammatory infiltrates and fibrotic remodeling, the autoimmune peripheral T cell response was comparable between groups, suggesting that progression towards DCM implicating some other mechanism driving progression. Additionally, qPCR for extracellular matrix and chemotactic genes among others showed a decrease in osteopontin (OPN) production in MIF-inhibited Dex treated mice. Subsequently, heart infiltrates were compared in Wt vs OPN knockout mice; though not statistically significant, they were decreased in OPN knockout mice. To determine a possible direct link between OPN and MIF, cardiac fibroblasts were treated with recombinant MIF and cytokine production evaluated by ELISA. Our findings reveal insights into the mechanisms driving progression of autoimmune myocarditis to DCM.
590 $a School code: 1283.
650 4 $a Immunology. $3 611031
650 4 $a Physiology. $3 518431
653 $a Autoimmune myocarditis
653 $a Dilated cardiomyopathy
653 $a Osteopontin
690 $a 0982
690 $a 0719
710 2 $a The University of Texas at San Antonio. $b Biology. $3 1676088
773 0 $t Masters Abstracts International $g 82-01.
790 $a 1283
791 $a M.S.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27994659